Biodesix to Provide COVID-19 Testing for Colorado State University Campus
Biodesix, Inc., a leading diagnostic company with a focus in lung disease, today announced plans to provide COVID-19 ddPCR diagnostic testing for Colorado State University (CSU) as students return to campus for the fall term, which begins August 24.
"The health and safety of our nation's students, and the faculty and staff that teach, guide, and mentor them, is of utmost importance to us. We are pleased to be able to support CSU in their efforts to help navigate a return to campus during this global pandemic," said Scott Hutton, CEO of Biodesix. "We understand that timely results are critical, and are proud that our tests with their rapid time to results are a part of this important plan."
The Biodesix SARS-CoV-2 ddPCR™ Test, which was released in partnership with Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), detects SARS-CoV-2 (the virus that causes COVID-19) and earned Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration earlier this year. Since April, Biodesix has processed more than 40,000 tests with results delivered in 24-48 hours.
Note Regarding Forward-Looking Statements